In the long-term study by Cozzi et al. [50] in which patients received octreotide LAR for up to 9 years, the greatest tumor volume reduction was observed in patients with higher baseline GH values, in those with the greatest changes in GH and IGF-1 during treatment, and in patients with macroadenomas (versus microadenomas; 81 vs 53 %, P = 0.0196). The gene discussed is IGF1; the disease is neoplasm.